Komori
K Pharma (4896) · InitiativeRestated

Research and Development of iPS Cell-Based Regenerative Medicine Pipelines

First written in FY2023-Q3. 7 of 8 entries say "Restated". Latest entry: FY2026-H1.

8entries
4years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023-Q3 – FY2026-H12023: 120232024: 320242025: 220252026: 22026
Same theme, other companies
Building a Next-Generation Pipeline in Regenerative Medicine and Maxillofacial ApplicationsA theme 2 companies write about · 0 as a headwind · 2 as a tailwind

0 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1RestatedAnnual report

    「In the regenerative medicine business, we are researching 5 development pipelines.」

    The company reiterates its policy of researching 5 development pipelines in regenerative medicine.
  2. FY2025RestatedAnnual report

    「In the regenerative medicine business, we are researching 5 development pipelines.」

    The company continues its policy of researching 5 development pipelines in regenerative medicine.
  3. FY2025-H1RestatedAnnual report

    「In the regenerative medicine business, we are researching 5 development pipelines.」

    The company reiterates its policy of researching 5 development pipelines in regenerative medicine.
  4. FY2024RestatedAnnual report

    「In the regenerative medicine business, we are researching 5 development pipelines.」

    The company reiterates its policy of researching 5 development pipelines in regenerative medicine.
  5. FY2024-H1RestatedAnnual report

    「In the regenerative medicine business, we are researching 5 development pipelines.」

    The company reiterates its policy of researching 5 development pipelines in regenerative medicine.
  6. FY2024-Q1RestatedAnnual report

    「In the regenerative medicine business, we are researching 5 development pipelines.」

    The company reiterates its policy of researching 5 development pipelines in regenerative medicine.
  7. FY2023RestatedAnnual report

    「In the regenerative medicine business, we are researching 5 development pipelines.」

    The company reiterates its policy of researching 5 development pipelines in regenerative medicine.
  8. FY2023-Q3First statedAnnual report

    「In the regenerative medicine business using iPS cells, we are researching 5 development pipelines.」

    The company is researching 5 development pipelines in its regenerative medicine business.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for K Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Research and Development of iPS Cell-Based Regenerative Medicine Pipelines | K Pharma,Inc. (4896) | Komori